Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    23-December-2000      
Issue 254 Next Update - 14:00 UTC 08:00 EST    24-December-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya FDA News:

Issues Safety Alert On Unapproved Goat Serum Treatment For HIV/AIDS

The Food and Drug Administration has alerted health care providers and patients to a potential safety concern involving an unapproved experimental product for HIV (human immunodeficiency virus, the AIDS virus)/AIDS. The sponsor of the product, Gary R. Davis, M.D., alleges that a batch of product has been stolen from a "storage facility" in Raleigh, N. C.

The sponsor has stated in a letter to the FDA that this batch of product has "the potential to be extremely dangerous" and has termed the product "contaminated medication." Dr Davis has further stated that "it is also possible that someone may try to sell this contaminated medication."

The FDA is advising health care providers and patients that goat antiserum to treat HIV/AIDS is not currently approved for the treatment of HIV/AIDS or for any human clinical study. This unapproved product, produced in goats as an antiserum against HIV/AIDS, was already the subject of a "clinical hold" by FDA, prohibiting its use until previously existing safety questions are resolved. The product sponsor himself is now warning of possible additional safety concerns about this specific batch of product. FDA urges that patients and health care providers exercise caution and be aware that there is no assurance of the safety of products which are not studied or produced in compliance with FDA regulations designed to protect patients.

Questions about this product and other unapproved investigational products may be directed to the FDA's Center for Biologics Evaluation and Research at 1-800-835-4709 or to the Office of Special Health Issues at 301-827-4460.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Vidyya Home |  Home Of Our Sponsor, Vidyya. | Vidyya Archives | Search Vidyya  | Visit Our Library | Subscribe To Our News Service | All About Us | Get Vidyya For Your Website
Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.